ALK launches tablet vaccine for tree pollen allergy
The allergy solutions company ALK launches its tablet vaccine for tree pollen allergy in Canada, where more than seven million people suffer from tree pollen allergy. The launch completes ALK's tablet portfolio in Canada, where the expected sales potential is in the high figures.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
Barely half-a-year after the Canadian health authorities approved the allergy company ALK's tablet vaccine for tree pollen allergy, the first vaccines are now available on the market in Canada.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
ALK buys shares in new biotech firm with experienced leader
For subscribers
